Humana’s Buy case hinges on a rebound in Medicare Advantage economics, improving operating efficiency, and CenterWell growth. The stock still faces meaningful reimbursement, Star Ratings, and medical cost risk.
Humana (HUM) earns a Buy rating for moderate-risk investors with a medium-term horizon. The investment case rests on a large Medicare Advantage platform, improving operating efficiency, CenterWell growth, and a path toward a sustainable 3% pretax margin by 2028. The main counterweight is that Humana remains heavily exposed to CMS reimbursement, Medicare Advantage Star Ratings, medical cost trends, and execution risk in its margin recovery.
The latest reported quarter provided both evidence of progress and evidence of unfinished work. Second-quarter 2026 revenue reached $40.9B, compared with $32.4B in the prior-year quarter. GAAP EPS was $5.73 and adjusted EPS was $7.61. Yet the consolidated benefit ratio rose to 91.1% from 89.7%, showing how quickly higher medical costs can absorb revenue growth.
At a quoted share price of $387.68 on October 8, 2026, HUM trades at 36.6x trailing earnings and 24.3x forward earnings. The analyst target in the financial data is $423.74, while the next-year EPS estimate is $16.67. The report's fair value estimate is $420.00, close to consensus because the earnings recovery is credible but still depends on Star Ratings improvement, plan design, and medical cost control.
Humana is not a simple low-volatility healthcare compounder. Its 2025 net margin was 0.9%, 2025 free cash flow was $375M, and debt was $12.5B against $4.2B of cash. The stock therefore suits investors willing to accept operational and regulatory volatility in exchange for exposure to a potential earnings normalization.
Humana is a Louisville, Kentucky-based healthcare company founded in 1961 and listed on the NYSE under HUM. It had 67,060 employees in the company profile and operates through two reportable segments: Insurance and CenterWell.
Humana's February 19, 2026 10-K reported that approximately 83% of 2025 premiums and services revenue came from federal government contracts. About 14% was tied to federal contracts with CMS for individual Medicare Advantage members in Florida. This government concentration provides scale and recurring enrollment, but it also makes reimbursement policy a central valuation variable.
At December 31, 2025, Humana had about 5.2 million individual Medicare Advantage members, including approximately 1.0 million in Florida. Florida generated roughly $17.8B of premiums revenue in 2025, or 14% of consolidated premiums and services revenue. That footprint gives HUM meaningful local density while increasing exposure to conditions in a single large state.
Insurance remains the economic center of Humana. The segment produced $39.1B of revenue in the second quarter of 2026, compared with $31.1B in the second quarter of 2025. Year-to-date revenue reached $77.2B, compared with $62.0B in the prior-year period.
Insurance segment income from operations was $820M in the second quarter and $2.3B year to date. The second-quarter benefit ratio was 91.2%, up from 89.9%, while the operating cost ratio improved to 7.1% from 8.3%. This combination captures the current Humana tradeoff: administrative efficiency is improving, but medical costs remain the larger earnings lever.
CenterWell generated $6.8B of second-quarter revenue, compared with $5.5B a year earlier, and $12.9B of year-to-date revenue. Segment income from operations rose to $466M in the quarter from $344M, while year-to-date operating income reached $755M.
CenterWell represented 15.3% of 2025 segment revenue, compared with 14.9% in 2024. The segment is still smaller than Insurance, but it has strategic importance because primary care, home health, pharmacy, and post-acute services can influence utilization, quality scores, and member retention.
Humana also won a statewide Illinois Medicaid managed care contract scheduled to begin in January 2027. The company was the only new entrant selected alongside five incumbent plans. That award expands the government-sponsored platform beyond Medicare Advantage and gives CenterWell and Insurance another channel for state-based growth.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Medicare Advantage is Humana's flagship product and the main driver of both its moat and its risk. Individual Medicare Advantage membership is expected to grow approximately 25% in 2026 over 2025, after a 7.3% decline in 2025. The 2026 recovery improves scale, but rapid membership growth also raises the importance of underwriting discipline and risk adjustment.
Humana's 2026 Medicare Advantage offerings cover 46 states and Washington, D.C., representing 85% of U.S. counties. Nationally, HUM held approximately 20% of Medicare Advantage enrollment in 2026, behind UnitedHealth's 26%. Scale is valuable in this market because fixed technology, compliance, clinical, and administrative costs spread across a large member base.
The product's economics depend heavily on Star Ratings. Humana reported that 2025 ratings reduced the number of plans receiving four stars or higher, creating a 2026 quality bonus headwind. Management is targeting a return to top-quartile Star Ratings in bonus year 2028 and defines top quartile as Star revenue per member per month 10% above the median of its top five competitors.
The 2027 plan strategy prioritizes higher-performing plans and plans with greater value-based care penetration. Management expects plan exits to affect approximately 600,000 members, with a recapture rate similar to 2025, when Humana recaptured just over 40% of exited membership. That approach sacrifices some volume to improve the quality of the earnings base.
Humana's strongest competitive advantage is the combination of Medicare Advantage scale and an integrated care platform. CenterWell gives HUM exposure to senior primary care, home health, pharmacy, and post-acute coordination rather than insurance underwriting alone. Senior-focused care delivery also creates a direct operating laboratory for value-based care.
The company is applying automation and AI to administrative work, utilization management, vendor operations, and information technology. Humana centralized utilization management across 11 markets, a change management said was producing general and administrative savings and a more consistent provider and member experience.
CarePlus operations were integrated into Humana's core platforms, eliminating redundancy while retaining the CarePlus brand in Florida. Management reported that operating model initiatives generated hundreds of millions of dollars of value during the first half of 2026. The value is meaningful, but the 2025 10-K also reported $449M of value creation initiative charges in 2025 and additional program charges are part of the transformation.
Humana added technology and insurance expertise to its board in 2026. Paul Smith, Anthropic's chief commercial officer, brings experience in technology transitions, while Fred Crawford brings more than 30 years of insurance and banking experience. The appointments support the company's stated shift toward a consumer healthcare model.
Humana does not operate a traditional manufactured-goods supply chain. Its operating chain runs from CMS and state contracts to member enrollment, provider contracting, utilization management, claims administration, pharmacy benefits, and CenterWell clinical services. The financial output depends on how efficiently those processes convert premiums into controlled medical costs and quality-adjusted reimbursement.
Management reported a 120-basis-point year-over-year decline in the consolidated operating cost ratio for the second quarter and expects a full-year reduction of approximately 150 basis points. Finance and human resources outsourcing expanded during 2026, while vendor optimization continued in information technology.
Medical cost management is focused on site-of-service selection, local contracting, member benefit incentives, and education. Humana reported both lower inpatient admissions per 1,000 members and lower unit costs for inpatient admissions. These operational improvements matter because the 2026 all-in medical and pharmacy trend assumption is 7% to 8%, with drug costs growing at a double-digit rate.
The operational model is improving, but the 2025 10-K recorded $329M of severance and employee-related charges within value creation initiatives. That cost demonstrates the near-term price of restructuring even as management targets lower recurring expenses.
Medicare Advantage is a concentrated national market. In 2026, UnitedHealth held 26% of enrollment, Humana held 20%, CVS Health held 12%, Kaiser held 6%, and Elevance Health held 5%. UnitedHealth and Humana together represented 46% of national enrollment, giving both companies scale in bidding, provider negotiations, analytics, and compliance.
The addressable opportunity extends beyond insurance premiums. The U.S. value-based healthcare services market was estimated at $4.01T in 2024 and is projected to grow at a 7.4% annual rate from 2025 to 2030. Care management solutions were estimated at $18.1B in 2025 and projected to reach $37.7B by 2031, a 13.0% annual growth rate.
Healthcare analytics is another important investment pool. The U.S. healthcare analytics market was estimated at $22.9B in 2025 and projected to reach $80.1B by 2031, representing a 23.3% annual growth rate. Humana's investments in automation, utilization management, and data-driven care fit these market trends, although the company must convert technology spending into lower claims costs and better Star Ratings.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Humana primarily serves older adults enrolled in Medicare Advantage, Medicare Part D, and Medicare Supplement products. It also serves Medicaid members, military personnel and dependents, and patients using CenterWell primary care, home health, pharmacy, hospice, and post-acute services.
The customer base is large and geographically distributed, with approximately 5.2 million individual Medicare Advantage members at the end of 2025 and plan offerings across 46 states plus Washington, D.C. Florida is especially important, with about 1.0 million individual Medicare Advantage members and 14% of consolidated premiums and services revenue tied to Florida federal contracts.
Customer retention depends on benefit design, service quality, provider access, clinical outcomes, and Star Ratings. Humana reported that new-member engagement was in line with, and on some measures higher than, renewing-member engagement. Key HEDIS improvement rates were 5% ahead of the prior year's pace on a per-member basis at the end of the second quarter.
The 2027 decision to exit lower-return plans shows that Humana is prioritizing member economics over enrollment at any price. That choice supports margin repair, but 600,000 members are expected to be affected by plan exits before recapture efforts.
UnitedHealth is Humana's largest Medicare Advantage competitor, with 26% of 2026 enrollment versus HUM's 20%. CVS Health and Aetna hold 12%, Kaiser holds 6%, and Elevance holds 5%. Centene and Molina are especially relevant in Medicaid managed care, while Centene is also a major stand-alone Part D sponsor.
Humana differentiates through Medicare specialization, senior-focused care delivery, value-based provider arrangements, and a large local-market footprint. The 10-K describes the health benefits industry as highly competitive and notes that some competitors have larger membership bases or greater financial resources. That scale gap limits pricing freedom in markets where UnitedHealth, CVS, or regional plans compete aggressively.
The competitive advantage is strongest when Humana's clinical platform produces better outcomes and higher Star revenue per member. It weakens when Star Ratings fall, medical trend exceeds pricing, or plan exits create member disruption. CenterWell's 130,900-patient year-to-date growth in senior primary care gives the company a tangible growth asset that many pure insurance competitors lack.
Humana's macro exposure is mainly regulatory rather than geopolitical. Approximately 83% of 2025 premiums and services revenue came from federal government contracts, making CMS payment rules, risk adjustment, Medicare Advantage benchmarks, Part D economics, and Medicaid contracts central to the earnings outlook.
The Inflation Reduction Act changed Medicare Part D economics. Beginning January 1, 2025, the coverage gap was eliminated and member out-of-pocket expenses for covered drugs were capped at $2,000. Humana's 2026 bid assumptions include 7% to 8% all-in cost trend, with medical costs growing at a lower rate and pharmacy costs growing at a double-digit rate.
CMS policy is also tightening utilization management oversight, prior authorization standards, health equity review, and interoperability requirements. Those rules increase compliance work, but Humana's centralization of utilization management across 11 markets and investment in automation align with the direction of regulation.
The current operating signal is mixed but improving. Humana reported slight inpatient favorability after approximately four months of completed claims data, while the second-quarter consolidated benefit ratio still increased to 91.1%. The earnings model therefore remains sensitive to medical utilization, drug costs, and CMS pricing decisions.
Debt of $12.5B versus $4.2B of cash leaves Humana with a leveraged balance sheet that is manageable, but not one that can absorb a prolonged earnings miss without pressure.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Second-quarter 2026 revenue jumped to $40.9B from $32.4B, yet the consolidated benefit ratio still climbed to 91.1%, showing how quickly medical costs can absorb growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Next-year EPS is estimated at $16.67, and the report’s case depends on Humana converting that forecast into a sustained recovery rather than a one-quarter rebound.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 24.3x forward earnings and a fair value estimate of $420, Humana trades near the report’s central valuation view despite a still-uncertain margin path.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The analyst target is $423.74 versus a quoted share price of $387.68, leaving modest upside if Humana can deliver on Star Ratings and cost control.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Humana is a recovery story with real operating assets behind it. Second-quarter revenue growth, CenterWell's $6.8B of quarterly revenue, lower operating costs, inpatient favorability, and a 6-of-7 completed-quarter EPS beat record support the constructive case.
The risks are equally concrete. The 2025 net margin was 0.9%, current ratio was 0.72, debt reached $14.3B by June 2026, and GAAP 2026 EPS guidance was reduced to at least $6.52. The business also relies heavily on CMS and federal contracts, while approximately 600,000 members are expected to be affected by 2027 plan exits.
For a medium-term investor, the balance of evidence supports a Buy rather than a Strong Buy. Humana has enough scale, growth, and operational momentum to justify exposure, but the stock still requires disciplined sizing until the Star Ratings recovery and the 2028 margin target become visible in reported earnings.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Humana Inc. (HUM) jumps after CMS 2027 Medicare Advantage Star Ratings showed 95% of members in plans rated 4 stars or above. The company’s flagship H5216 contract also returned to 4 stars, restoring bonus-payment eligibility and improving the outlook for revenue and margins.
Humana Inc. (HUM) climbs after CMS released 2027 Medicare Advantage Star Ratings, lifting its largest contract back to 4 stars from 3.5. The upgrade improves the outlook for bonus payments, rebates, and enrollment competitiveness, while recent earnings strength adds support to the move.
Humana Inc. (HUM) beat second-quarter EPS and revenue estimates, yet the stock dropped as investors focused on Medicare Advantage margin repair, cost-ratio improvement, and 2027 bid strategy. This deep-dive examines why the earnings beat wasn’t enough to offset longer-term execution risks.